Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).
Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).
Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sugemalimab | WBP-3155; CS-1001 | Approved | Cstone Pharmaceuticals (Suzhou) Co Ltd | 择捷美 | Mainland China | Carcinoma, Non-Small-Cell Lung | Cstone Pharmaceuticals (Suzhou) Co Ltd | 2021-12-20 | Prostatic Neoplasms; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Pancreatic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Envafolimab | KN-035; ASC-22 | Approved | Suzhou Alphamab Co Ltd | ENWEIDA, 恩维达 | Mainland China | Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer | 3d Medicines (Sichuan) Co Ltd | 2021-11-25 | Sepsis; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Sarcoma; Microsatellite instability-high cancer; Neoplasms, Multiple Primary; Colonic Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Hepatitis B, Chronic; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Liver Neoplasms; HIV Infections; Shock, Septic | Details |
| Durvalumab | 28X28X9-OKV (UNII code); MEDI-4736 | Approved | Medimmune Llc | 英飞凡, Imfinzi | United States | Small Cell Lung Carcinoma | Astrazeneca Uk Ltd | 2018-02-16 | Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Gallbladder Neoplasms; Primary Myelofibrosis; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Genital Neoplasms, Female; Testicular Neoplasms; Carcinoma, Squamous Cell; Pinealoma; Colorectal Neoplasms; Urologic Neoplasms; Microsatellite Instability; Nasopharyngeal Carcinoma; Vulvar Neoplasms; Sarcoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Thyroid Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Laryngeal Diseases; Dysgerminoma; Adenocarcinoma; Carcinoma, Endometrioid; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Mouth Neoplasms; Lymphoma, T-Cell, Cutaneous; Urogenital Neoplasms; Endometrial Neoplasms; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Carcinoma; Pancreatic Neoplasms; Polycythemia Vera; Re | Details |
| Atezolizumab | RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A | Approved | Genentech Inc | 泰圣奇, Tecentriq | Mainland China | Carcinoma, Non-Small-Cell Lung | Roche (China) Holding Ltd | 2016-05-18 | Genital Neoplasms, Female; Uterine Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Neoplasms, Unknown Primary; Lung Neoplasms; Gallbladder Neoplasms; Urogenital Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Sezary Syndrome; Bile Duct Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Lymphoma, Follicular; Sarcoma; Microsatellite Instability; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Liposarcoma, Myxoid; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Urethral Neoplasms; Thyroid Neoplasms; Thymoma; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lymphoma, T-Cell, Cutaneous; Penile Neoplasms; Esophageal Squamous Cell Carcinoma; Glioma; Lymphoma; Carcinoma, Renal Cell; Kidney Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Anus Neoplasms; Rectal Neoplasms | Details |
| Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | EU | Carcinoma, Transitional Cell | Merck Europe Bv | 2017-03-23 | Lymphoma; Vulvar Neoplasms; Lymphoma, Follicular; Osteosarcoma; Lymphoma, Extranodal NK-T-Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Meningeal Neoplasms; Testicular Neoplasms; Glioma; Penile Neoplasms; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Testicular Diseases; Carcinoma, Squamous Cell; Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Adenocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Meningioma; Neoplasms, Germ Cell and Embryonal; Gastrointestinal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Second Primary; Uterine Cervical Neoplasms; Lentivirus Infections; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Carcinoma, Merkel Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Anus Neoplasms; Pancreatic Neoplasms; Hodgkin Disease; Neoplasms; Gl | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
| IMM2505 | IMM2505 | Phase 1 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours | Details |
| 89Zr-KN035（Wuxi No. 4 People's Hospital） | Clinical | Wuxi No. 4 People | Solid tumours | Details | |
| Carrizumab | Phase 2 Clinical | Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details | ||
| PM-1003 | PM1003 | Phase 2 Clinical | Biotheus Inc | Solid tumours | Details |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Neoplasms | Details | |
| ADG-104 | ADG-104; ADG104 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc | Neoplasms | Details |
| JS-003 | JS-003 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours | Details |
| RG-6084 | RG-6084; RO-7191863 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B | Details |
| QL-415 | QL-415 | Phase 1 Clinical | Neoplasms | Details | |
| QL-301 | QL-301 | Phase 1 Clinical | Neoplasms | Details | |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
| SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
| HB-0028 | HB-0028 | Phase 1 Clinical | Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biotech Co Ltd | Solid tumours | Details |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| TT-00420/Atezolizumab | Phase 1 Clinical | Gastrointestinal Neoplasms | Details | ||
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| PM-1022 | PM-1022 | Phase 1 Clinical | Biotheus Inc | Neoplasms | Details |
| Sudubrilimab | HS-636 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Triple Negative Breast Neoplasms; Neoplasms; Primary mediastinal B cell lymphoma | Details |
| IMM-2510 | IMM-2510 | Phase 1 Clinical | Solid tumours | Details | |
| FH-2001 | FH-2001 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical Development Ltd | Solid tumours | Details |
| HB-0025 | HB0025 | Phase 1 Clinical | Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| GT-90008 | GS-19-PLB-1C; GT-90008; GS-19 | Phase 1 Clinical | Solid tumours | Details | |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Solid tumours; Neoplasms | Details |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours; Neoplasms; Contrast agents | Details |
| Garivulimab | BGB-A333 | Phase 1 Clinical | Beigene Ltd | Neoplasms | Details |
| Lesabelimab | BC-003 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd | Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms | Details |
| FPT-155 | CD80-Fc; FPT-155 | Five Prime Therapeutics Inc | Details | ||
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours | Details |
| MT-6402 | MT-6402; MT-64-6402 | Molecular Templates | Details | ||
| KN-052 | KN-052 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Solid tumours | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Gastrointestinal Diseases | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Sichuan University | Details | |||
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd | Solid tumours | Details |
| TJ-L14B | ABL-503; TJ-L14B/ABL503; ABL503 | I-Mab Biopharma Co Ltd | Details | ||
| GNC-035 quadr-specific antibody（baili） | GNC-035 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Metastatic breast cancer | Details |
| PF-07257876 | Details | ||||
| KD-033 | KD-033 | Takeda Pharma | Details | ||
| LBL-024 | LBL024; LBL-024 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Solid tumours; Neoplasms | Details |
| QLF31907 | QLF31907; QLF-31907 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| CA-170 | CA-170; AUPM-170 | Aurigene | Details | ||
| FS-222 | FS-222 | F-star Beta Ltd | Details | ||
| CN-202 | CN-202 | Phase 1 Clinical | Tongrun Biomedicine (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| TQB-2868 | TQB-2868 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | Imugene Ltd, City Of Hope National Medical Center | Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Lymphoma | Details |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| sirpiglenastat | DRP-104 | Dracen Pharmaceuticals Inc | Details | ||
| Pacmilimab | CX-072 | Cytomx Therapeutics | Details | ||
| PRS-344 | PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc, Laboratoires Servier | Solid tumours | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Numab Therapeutics Ag, Cstone Pharmaceuticals | Solid tumours; Neoplasms | Details |
| ATG-101 | ATG-101 | Phase 1 Clinical | Antengene Corporation Co Ltd | Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma | Details |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Lymphoma, T-Cell; Leukemia, Myeloid, Acute | Details |
| BMS-986189 | BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 | Bristol-Myers Squibb Company | Details | ||
| 89Zr-durvalumab | Radboud University Nijmegen | Details | |||
| GS-4224 | GS-4224 | Gilead Sciences Inc | Details | ||
| Opucolimab | HLX-20 | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Neoplasms | Details |
| c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | The Second Hospital Of Nanjing Medical University | Details | |||
| MCLA-145 | MCLA-145 | Incyte Corp, Merus | Details | ||
| LOR-S03 | CDX-527 | Celldex Therapeutics | Details | ||
| Lodapolimab | LY-3300054 | Eli Lilly And Company | Details | ||
| MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours | Details |
| Davoceticept | ALPN-202 | Alpine Immune Sciences | Details | ||
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Triple Negative Breast Neoplasms | Details |
| ABSK-043 | ABSK043 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| TQB-2858 | TQB-2858 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Pancreatic Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
| BS-006 | BS-006 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| GR-1405 | GR-1405 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma | Details |
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BR-102 | BR102 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Emdifen | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences | Solid tumours | Details | |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Solid tumours; Neoplasms | Details |
| RC-98 | RC-98; RC98 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| FS 118 | FS-118 | Phase 2 Clinical | Merck Serono, F-Star | Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis | Details |
| Cosibelimab | CK-301; TG-1501 | Phase 3 Clinical | Dana-Farber Cancer Institute | Lymphoma; Carcinoma, Non-Small-Cell Lung | Details |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 3 Clinical | Bristol-Myers Squibb Company | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Liver Neoplasms; Rectal Neoplasms; Sepsis; Hodgkin Disease; Colonic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| ACT-001 | ACT-001 | Phase 2 Clinical | Accendatech | Glioblastoma; Ganglioglioma; Optic Neuritis; Central Nervous System Neoplasms; Neuromyelitis Optica; Breast Neoplasms; Glioma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Neoplasms; Myelodysplastic Syndromes; Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute | Details |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Mabspace Biosciences Co Ltd | Solid tumours; Neoplasms; Papillomavirus Infections | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriginCell Therapeutics Co Ltd | Solid tumours | Details |
| HB-0036 | HB-0036 | Phase 2 Clinical | Huabo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| PM-8002 | PM8002; PM-8002 | Phase 2 Clinical | Biotheus Inc | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Carcinoma, Hepatocellular | Details |
| BAT-7104 | BAT-7104 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| Erfonrilimab | KN-046; KN046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd, Suzhou Alphamab Co Ltd | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Thymoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Retlirafusp alfa | SHR-1701 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 2 Clinical | Incyte Corp | Solid tumours; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| IMC-001 | IMC-001; STI-3031; STI-A1015 | Phase 2 Clinical | Sorrento Therapeutics | Lymphoma, T-Cell, Peripheral; Solid tumours; Biliary Tract Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis | Details |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Serositis; Ascites | Details | |
| TQB-2450 | APL-502; CBT-502; TQ-B2450 | Phase 3 Clinical | Cbt | Carcinoma, Squamous Cell; Primary mediastinal B cell lymphoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Stroke; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Esophageal Diseases; Digestive System Diseases; Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Biliary Tract Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Esophageal Neoplasms; Lymphoma, B-Cell; Gastrointestinal Diseases; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Digestive System Neoplasms | Details |
| SGN-PDL1V | SGN-PDL1V | Phase 1 Clinical | Seagen Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| Acasunlimab | PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 | Phase 2 Clinical | Genmab, Biontech Se | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Betifisolimab | MSB-2311 | Phase 1 Clinical | Mabspace Biosciences Co Ltd | Solid tumours | Details |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biomedical Technology Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
